- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba unveils wide-bore 3T MR scanner
Toshiba laid the groundwork for entering the 3T marketplace in the U.S. with the unveiling of its Vantage Titan 3T system at RSNA 2009. The work-in-progress, which is pending FDA clearance, leapfrogs earlier generations of 3T scanners with a 71-cm tapered aperture and Pianissimo noise reduction technology.
Toshiba laid the groundwork for entering the 3T marketplace in the U.S. with the unveiling of its Vantage Titan 3T system at RSNA 2009. The work-in-progress, which is pending FDA clearance, leapfrogs earlier generations of 3T scanners with a 71-cm tapered aperture and Pianissimo noise reduction technology.
The new wide-bore system incorporates the ability to perform contrast-free MR angiography exams, including Fresh Blood Imaging (FBI) for evaluating peripheral vascular diseases of the lower legs and extremities, Contrast-free Improved Angiography (CIA) for easier visualization of smaller vessels, Time-Spatial Labeling Inversion Pulse (Time-SLIP) for evaluating hemodynamic functional assessments and visualization of vascular structures, and Time and Space Angiography (TSA) to create noncontrast time-resolved imaging with high temporal resolution.
The 3T system utilizes Toshiba's Atlas coil technology integrated into the table to allow patients to be examined without having to be continually repositioned for different exams. The product is being designed with a new user interface called M-Power that promises to simplify training and operation.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
Can AI Automate BPE Assessment of Dense Breasts on MRI?
April 3rd 2024An MRI-based machine learning model demonstrated a comparable background parenchymal enhancement (BPE) hazard ratio to that of manual BPE assessment for breast cancer, according to a study of over 4,500 women with dense breasts.
